INTRODUCTION AND HYPOTHESIS: Although in-depth qualitative information is critical to understanding patients' symptom experiences and to developing patient-centered outcome measures, only one previous qualitative study has assessed urological chronic pelvic pain syndrome (UCPPS) symptom exacerbations ("flares"). METHODS: We conducted eight focus groups of female UCPPS (interstitial cystitis/bladder pain syndrome) patients at four sites from the MAPP Research Network (n = 57, mean = 7/group) to explore the full spectrum of flares and their impact on patients' lives. RESULTS: Flare experiences were common and varied widely in terms of UCPPS symptoms involved, concurrent nonpelvic symptoms (e.g., diarrhea), symptom intensity (mild to severe), duration (minutes to years), and frequency (daily to < once/year), although the most commonly described flares were painful flares lasting days. These latter flares were also most disruptive to participants' lives, causing some to cancel social events, miss work or school, and in the worst cases, go to the emergency room or on disability leave. Participants also reported a longer-term impact of flares, including negative effects on their sexual functioning and marital, family, and social relationships; and the loss of employment or limited career or educational advancement. Emerging themes included the need for a sense of control over unpredictable symptoms and reduced social engagement. CONCLUSIONS: Given their negative impact, future research should focus on approaches to prevent flares, and to reduce their frequency, severity, and/or duration. Patients' quality of life may also be improved by providing them with a sense of control over their symptoms through ready access to flare medications/therapy, and by engaging them socially.
INTRODUCTION AND HYPOTHESIS: Although in-depth qualitative information is critical to understanding patients' symptom experiences and to developing patient-centered outcome measures, only one previous qualitative study has assessed urological chronic pelvic pain syndrome (UCPPS) symptom exacerbations ("flares"). METHODS: We conducted eight focus groups of female UCPPS (interstitial cystitis/bladder pain syndrome) patients at four sites from the MAPP Research Network (n = 57, mean = 7/group) to explore the full spectrum of flares and their impact on patients' lives. RESULTS: Flare experiences were common and varied widely in terms of UCPPS symptoms involved, concurrent nonpelvic symptoms (e.g., diarrhea), symptom intensity (mild to severe), duration (minutes to years), and frequency (daily to < once/year), although the most commonly described flares were painful flares lasting days. These latter flares were also most disruptive to participants' lives, causing some to cancel social events, miss work or school, and in the worst cases, go to the emergency room or on disability leave. Participants also reported a longer-term impact of flares, including negative effects on their sexual functioning and marital, family, and social relationships; and the loss of employment or limited career or educational advancement. Emerging themes included the need for a sense of control over unpredictable symptoms and reduced social engagement. CONCLUSIONS: Given their negative impact, future research should focus on approaches to prevent flares, and to reduce their frequency, severity, and/or duration. Patients' quality of life may also be improved by providing them with a sense of control over their symptoms through ready access to flare medications/therapy, and by engaging them socially.
Authors: J Curtis Nickel; Dean A Tripp; Michel Pontari; Robert Moldwin; Robert Mayer; Lesley K Carr; Raggi Doggweiler; Claire C Yang; Nagendra Mishra; Jorgen Nordling Journal: J Urol Date: 2010-01 Impact factor: 7.450
Authors: J Quentin Clemens; Elizabeth A Calhoun; Mark S Litwin; Mary McNaughton-Collins; John W Kusek; Evelyn M Crowley; J Richard Landis Journal: Urology Date: 2009-10-02 Impact factor: 2.649
Authors: J Quentin Clemens; Alisa Stephens-Shields; Bruce D Naliboff; H Henry Lai; Larissa Rodriguez; John N Krieger; David A Williams; John W Kusek; J Richard Landis Journal: J Urol Date: 2018-01-04 Impact factor: 7.450
Authors: J Quentin Clemens; Chris Mullins; A Lenore Ackerman; Tamara Bavendam; Adrie van Bokhoven; Benjamin M Ellingson; Steven E Harte; Jason J Kutch; H Henry Lai; Katherine T Martucci; Robert Moldwin; Bruce D Naliboff; Michel A Pontari; Siobhan Sutcliffe; J Richard Landis Journal: Nat Rev Urol Date: 2019-03 Impact factor: 14.432
Authors: Gregory Kanter; Katherine A Volpe; Gena C Dunivan; Sara B Cichowski; Peter C Jeppson; Rebecca G Rogers; Yuko M Komesu Journal: Int Urogynecol J Date: 2016-08-31 Impact factor: 2.894
Authors: Siobhan Sutcliffe; Thomas Jemielita; H Henry Lai; Gerald L Andriole; Catherine S Bradley; J Quentin Clemens; Robert Gallop; Thomas M Hooton; Karl J Kreder; John N Krieger; John W Kusek; Jennifer Labus; M Scott Lucia; Sean Mackey; Bruce D Naliboff; Nancy A Robinson; Larissa V Rodriguez; Alisa Stephens-Shields; Adrie van Bokhoven; Kathleen Y Wolin; Yan Yan; Claire C Yang; J Richard Landis; Graham A Colditz Journal: J Urol Date: 2017-12-27 Impact factor: 7.450
Authors: Siobhan Sutcliffe; Robert Gallop; Hing Hung Henry Lai; Gerald L Andriole; Catherine S Bradley; Gisela Chelimsky; Thomas Chelimsky; James Quentin Clemens; Graham A Colditz; Bradley Erickson; James W Griffith; Jayoung Kim; John N Krieger; Jennifer Labus; Bruce D Naliboff; Larissa V Rodriguez; Suzette E Sutherland; Bayley J Taple; John Richard Landis Journal: BJU Int Date: 2019-05-29 Impact factor: 5.588
Authors: H Henry Lai; Joel Vetter; Joseph Song; Gerald L Andriole; Graham A Colditz; Siobhan Sutcliffe Journal: Urology Date: 2019-01-22 Impact factor: 2.649
Authors: Andrew Schrepf; Michael A O'Donnell; Yi Luo; Catherine S Bradley; Karl J Kreder; Susan K Lutgendorf Journal: Urology Date: 2016-01-06 Impact factor: 2.649
Authors: Jieni Li; Tiange Yu; Irum Javed; Chaitanya Siddagunta; Ratna Pakpahan; Marvin E Langston; Leslie K Dennis; Darrel M Kingfield; David J Moore; Gerald L Andriole; H Henry Lai; Graham A Colditz; Siobhan Sutcliffe Journal: Neurourol Urodyn Date: 2020-05-04 Impact factor: 2.696